American Society of Hematology

banner image

CME, MOC, and Certificates of Attendance

Obtain CME/MOC or request a Certificate of Attendance for the 59th ASH Annual Meeting.

Learn more
banner image

2018 Highlights of ASH

Attend one of eight Highlights of ASH meetings featuring expert analysis of stand-out abstracts and sessions from the 59th ASH Annual Meeting.

Learn more
banner image

Now Available for Comment: Draft Recommendations on VTE

ASH is seeking public comment on draft recommendations for two guidelines on venous thromboembolism (VTE).

Learn more
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 17,000 hematologists working to conquer blood diseases.

Learn more
  • Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term

    In four clinical trials being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

  • American Society of Hematology to Recognize Choosing Wisely Champions at 59th Annual Meeting

    The American Society of Hematology will recognize three Choosing Wisely® Champions, practitioners working to tackle overuse of hematology tests and treatments, today at its 59th annual meeting in Atlanta.

  • People Aged 75 Years and Older Are Underrepresented in Blood Cancer Clinical Trials

    In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

  • CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

    For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta spotlight the emerging role played by chimeric antigen receptor (CAR) T-cell therapies in helping individuals mount a clinical response and, in some cases, achieve durable remission.

View all press releases
  • 2017 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2017.

  • 2017 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2017.

  • 2017 ASH Advocacy Efforts to Ensure Patient Access to Care

    ASH was very vocal on Congress’s repeated attempts to repeal and replace the Affordable Care Act (ACA). ASH opposed the legislation introduced in the House and the Senate and sent numerous letters to Congress outlining priorities and expressing concerns.

  • 2017 Physician Payment Advocacy Highlights

    In 2017, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.

View all policy news
View all Hematologist articles